CMOPF
Price
$83.60
Change
+$8.60 (+11.47%)
Updated
Sep 16 closing price
Capitalization
1.28B
NVS
Price
$123.33
Change
+$1.10 (+0.90%)
Updated
Sep 26, 01:21 PM (EDT)
Capitalization
239.68B
32 days until earnings call
Interact to see
Advertisement

CMOPF vs NVS

Header iconCMOPF vs NVS Comparison
Open Charts CMOPF vs NVSBanner chart's image
Cosmo Pharmaceuticals
Price$83.60
Change+$8.60 (+11.47%)
Volume$100
Capitalization1.28B
Novartis AG
Price$123.33
Change+$1.10 (+0.90%)
Volume$260
Capitalization239.68B
CMOPF vs NVS Comparison Chart in %
Loading...
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMOPF vs. NVS commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMOPF is a Buy and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (CMOPF: $83.60 vs. NVS: $122.23)
Brand notoriety: CMOPF and NVS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: CMOPF: 63% vs. NVS: 103%
Market capitalization -- CMOPF: $1.28B vs. NVS: $239.68B
CMOPF [@Pharmaceuticals: Major] is valued at $1.28B. NVS’s [@Pharmaceuticals: Major] market capitalization is $239.68B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $640.6B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $87.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMOPF’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • CMOPF’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, both CMOPF and NVS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMOPF’s TA Score shows that 2 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).

  • CMOPF’s TA Score: 2 bullish, 2 bearish.
  • NVS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than CMOPF.

Price Growth

CMOPF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.07%. For the same industry, the average monthly price growth was -0.30%, and the average quarterly price growth was +12.81%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.07% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($240B) has a higher market cap than CMOPF($1.28B). CMOPF has higher P/E ratio than NVS: CMOPF (19.83) vs NVS (17.82). NVS YTD gains are higher at: 30.131 vs. CMOPF (24.916). NVS has higher annual earnings (EBITDA): 22.7B vs. CMOPF (84.7M). NVS has more cash in the bank: 7B vs. CMOPF (127M). CMOPF has less debt than NVS: CMOPF (2.7M) vs NVS (32.6B). NVS has higher revenues than CMOPF: NVS (55.2B) vs CMOPF (182M).
CMOPFNVSCMOPF / NVS
Capitalization1.28B240B1%
EBITDA84.7M22.7B0%
Gain YTD24.91630.13183%
P/E Ratio19.8317.82111%
Revenue182M55.2B0%
Total Cash127M7B2%
Total Debt2.7M32.6B0%
FUNDAMENTALS RATINGS
CMOPF vs NVS: Fundamental Ratings
CMOPF
NVS
OUTLOOK RATING
1..100
4669
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
10016
SMR RATING
1..100
6129
PRICE GROWTH RATING
1..100
4455
P/E GROWTH RATING
1..100
4778
SEASONALITY SCORE
1..100
n/a45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (14) in the Pharmaceuticals Major industry is in the same range as CMOPF (18) in the null industry. This means that NVS’s stock grew similarly to CMOPF’s over the last 12 months.

NVS's Profit vs Risk Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for CMOPF (100) in the null industry. This means that NVS’s stock grew significantly faster than CMOPF’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as CMOPF (61) in the null industry. This means that NVS’s stock grew similarly to CMOPF’s over the last 12 months.

CMOPF's Price Growth Rating (44) in the null industry is in the same range as NVS (55) in the Pharmaceuticals Major industry. This means that CMOPF’s stock grew similarly to NVS’s over the last 12 months.

CMOPF's P/E Growth Rating (47) in the null industry is in the same range as NVS (78) in the Pharmaceuticals Major industry. This means that CMOPF’s stock grew similarly to NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMOPFNVS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
41%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
14%
Bullish Trend 2 days ago
52%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
40%
MACD
ODDS (%)
Bullish Trend 2 days ago
22%
Bearish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
24%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
26%
Bearish Trend 2 days ago
37%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
50%
Declines
ODDS (%)
N/A
Bearish Trend 9 days ago
45%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
55%
Aroon
ODDS (%)
Bearish Trend 2 days ago
6%
Bullish Trend 2 days ago
39%
View a ticker or compare two or three
Interact to see
Advertisement
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LFBB168.56N/A
N/A
LifeX 2063 Longevity Income ETF
IFN14.64-0.05
-0.34%
India Fund (The)
IUSV98.73-0.40
-0.40%
iShares Core S&P US Value ETF
IWFG52.97-0.42
-0.79%
NYLI Winslow Focused Large Cap Gr ETF
GSC52.73-0.42
-0.80%
Goldman Sachs Small Cap Equity ETF

CMOPF and

Correlation & Price change

A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMOPF
1D Price
Change %
CMOPF100%
N/A
GSK - CMOPF
22%
Poorly correlated
-1.64%
NVS - CMOPF
21%
Poorly correlated
-0.63%
CHGCY - CMOPF
7%
Poorly correlated
-3.23%
DSNKY - CMOPF
5%
Poorly correlated
-1.09%
CSPCY - CMOPF
4%
Poorly correlated
-0.94%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.63%
GSK - NVS
67%
Closely correlated
-1.64%
AZN - NVS
61%
Loosely correlated
-2.43%
PFE - NVS
58%
Loosely correlated
-2.03%
JNJ - NVS
54%
Loosely correlated
+0.59%
SNY - NVS
50%
Loosely correlated
-2.87%
More